IN2014DN10889A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN10889A IN2014DN10889A IN10889DEN2014A IN2014DN10889A IN 2014DN10889 A IN2014DN10889 A IN 2014DN10889A IN 10889DEN2014 A IN10889DEN2014 A IN 10889DEN2014A IN 2014DN10889 A IN2014DN10889 A IN 2014DN10889A
- Authority
- IN
- India
- Prior art keywords
- cell
- car
- conjugate
- drug
- molecule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671518P | 2012-07-13 | 2012-07-13 | |
| PCT/US2013/050272 WO2014011987A1 (fr) | 2012-07-13 | 2013-07-12 | Compositions et procédés pour la régulation de lymphocytes t car |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10889A true IN2014DN10889A (fr) | 2015-09-11 |
Family
ID=49916567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10889DEN2014 IN2014DN10889A (fr) | 2012-07-13 | 2013-07-12 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20150140019A1 (fr) |
| EP (1) | EP2872218A4 (fr) |
| JP (1) | JP2015525765A (fr) |
| KR (1) | KR20150030724A (fr) |
| CN (1) | CN104507537A (fr) |
| AU (1) | AU2013289970A1 (fr) |
| BR (1) | BR112015000310A2 (fr) |
| CA (1) | CA2878856A1 (fr) |
| EA (1) | EA201590207A1 (fr) |
| IL (1) | IL236679A0 (fr) |
| IN (1) | IN2014DN10889A (fr) |
| MX (1) | MX2015000428A (fr) |
| SG (1) | SG11201408398UA (fr) |
| WO (1) | WO2014011987A1 (fr) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY190711A (en) | 2013-02-20 | 2022-05-12 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| WO2014145252A2 (fr) | 2013-03-15 | 2014-09-18 | Milone Michael C | Ciblage de cellules cytotoxiques par des récepteurs chimériques pour une immunothérapie adoptive |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| US10640569B2 (en) | 2013-12-19 | 2020-05-05 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| WO2015095811A2 (fr) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Polythérapie comprenant un vaccin à base de néoantigènes |
| WO2015090229A1 (fr) | 2013-12-20 | 2015-06-25 | Novartis Ag | Récepteur d'antigène chimérique régulable |
| WO2015112626A1 (fr) | 2014-01-21 | 2015-07-30 | June Carl H | Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe |
| RU2718542C2 (ru) | 2014-04-07 | 2020-04-08 | Новартис Аг | Лечение злокачественной опухоли с использованием химерного рецептора антигена против cd19 |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| SG10201913782UA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| MX2017001008A (es) | 2014-07-21 | 2017-08-02 | Novartis Ag | Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33. |
| MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| BR112017005390A2 (pt) | 2014-09-17 | 2017-12-12 | Novartis Ag | células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| WO2016073875A1 (fr) * | 2014-11-06 | 2016-05-12 | University Of Maryland, Baltimore | Variants de cd8α et de récepteur de cellules t et procédés pour les utiliser dans la modulation des réponses de cellules immunitaires |
| CA2969384A1 (fr) * | 2014-12-17 | 2016-06-23 | Cellectis | Recepteur d'antigene chimerique inhibiteur (icar ou n-car) exprimant un domaine de transduction non lymphocytaire t |
| EP3234193B1 (fr) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Biomarqueurs moléculaires pour l'immunothérapie d'un cancer |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| KR20170093254A (ko) | 2014-12-29 | 2017-08-14 | 노파르티스 아게 | 키메라 항원 수용체-발현 세포를 제조하는 방법 |
| WO2016115482A1 (fr) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Promoteurs de phosphoglycérate kinase 1 (pgk) et procédés d'utilisation pour l'expression d'un récepteur antigénique chimérique |
| JP2018504143A (ja) | 2015-01-26 | 2018-02-15 | セレクティスＣｅｌｌｅｃｔｉｓ | がん免疫治療のための抗ｈｓｐ７０特異的キメラ抗原受容体（ｃａｒ） |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| SI3280729T1 (sl) | 2015-04-08 | 2022-09-30 | Novartis Ag | Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR) |
| EP4234685A3 (fr) | 2015-04-17 | 2023-09-06 | Novartis AG | Procédés pour améliorer l'efficacité et l'expansion de cellules exprimant un récepteur antigénique chimérique |
| IL302102A (en) | 2015-05-20 | 2023-06-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| WO2016205749A1 (fr) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Nouvelles enzymes crispr et systèmes associés |
| CN115058395A (zh) * | 2015-06-25 | 2022-09-16 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| CA2992551A1 (fr) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methodes pour ameliorer l'efficacite et l'expansion de cellules immunitaires |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| CN108463469B (zh) * | 2015-08-17 | 2022-12-13 | 首尔大学校产学协力团 | 一种与抗可替宁抗体连接的嵌合抗原受体及其用途 |
| CN108135932A (zh) | 2015-08-28 | 2018-06-08 | 宾夕法尼亚大学董事会 | 表达嵌合细胞内信号传导分子的细胞的方法和组合物 |
| CN108348551A (zh) | 2015-08-28 | 2018-07-31 | 宾夕法尼亚大学董事会 | 表达嵌合细胞内信号传导分子的细胞的方法和组合物 |
| EP3344996A2 (fr) | 2015-09-03 | 2018-07-11 | The Trustees Of The University Of Pennsylvania | Biomarqueurs prédictifs du syndrome de libération de cytokines |
| WO2017069958A2 (fr) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation de nouvelles cibles de points de contrôle immunitaires |
| WO2017075451A1 (fr) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de pou2af1 |
| WO2017075465A1 (fr) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de gata3 |
| EP3368689B1 (fr) | 2015-10-28 | 2020-06-17 | The Broad Institute, Inc. | Compositions d'évaluation et de modulation des réponses immunitaires à l'aide de signatures génétiques de cellules immunitaires |
| CA3005878A1 (fr) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Heterodimeres dans l'immunite de l'interleukine 12b (p40) de type antigene lymphocytaire cd5 (cd5l) |
| EP3393504A1 (fr) | 2015-12-22 | 2018-10-31 | Novartis AG | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
| WO2017165683A1 (fr) | 2016-03-23 | 2017-09-28 | Novartis Ag | Mini-corps sécrétés par des cellules et leurs usages |
| AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| WO2018035364A1 (fr) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Produit et procédés utiles pour moduler et évaluer des réponses immunitaires |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| CA3039646A1 (fr) | 2016-10-07 | 2018-04-12 | Novartis Ag | Recepteurs antigeniques chimeriques pour le traitement du cancer |
| US20200016202A1 (en) | 2016-10-07 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2018073394A1 (fr) * | 2016-10-19 | 2018-04-26 | Cellectis | Récepteurs d'antigènes chimériques induisant la mort cellulaire |
| WO2018140391A1 (fr) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions et procédés de détection d'un variant mutant d'un polynucléotide |
| EP4043485A1 (fr) | 2017-01-26 | 2022-08-17 | Novartis AG | Compositions de cd28 et procédés pour une thérapie à base de récepteur antigénique chimérique |
| ES2965475T3 (es) | 2017-02-12 | 2024-04-15 | Biontech Us Inc | Métodos y composiciones basados en HLA y usos de los mismos |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| CN110832075A (zh) | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| WO2018183908A1 (fr) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions et méthodes de traitement de tumeurs ovariennes |
| EP3606518A4 (fr) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | Méthodes et compositions de détection et de modulation d'une signature génique de résistance à l'immunothérapie d'un cancer |
| EP3610266A4 (fr) | 2017-04-12 | 2021-04-21 | Massachusetts Eye and Ear Infirmary | Signature tumorale pour métastase, compositions de matière et leurs procédés d'utilisation |
| US20210293783A1 (en) | 2017-04-18 | 2021-09-23 | The General Hospital Corporation | Compositions for detecting secretion and methods of use |
| EP3638218A4 (fr) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | Compositions et procédés ciblant le composant 3 du complément pour inhiber la croissance tumorale |
| US20220233588A1 (en) | 2017-06-30 | 2022-07-28 | Cellectis | Cellular immunotherapy for repetitive administration |
| JP2020535802A (ja) | 2017-09-21 | 2020-12-10 | ザ・ブロード・インスティテュート・インコーポレイテッド | 標的化核酸編集のための系、方法、及び組成物 |
| WO2019084055A1 (fr) | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | Classification de variation génétique à partir de transcriptomes unicellulaires |
| WO2019094983A1 (fr) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Méthodes et compositions de traitement du cancer par ciblage de la voie clec2d-klrb1 |
| US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| CN112055595A (zh) | 2018-01-22 | 2020-12-08 | 恩多塞特公司 | Car t细胞的使用方法 |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| JP7438988B2 (ja) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | Ｂｃｍａキメラ抗原受容体及びその使用 |
| WO2020041384A1 (fr) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | Dérivés de 3-phényl-2-cyano-azétidine inhibiteurs de l'activité nucléase guidée par l'arn |
| WO2020041387A1 (fr) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Modifications de domaine de dégradation pour la régulation spatio-temporelle de nucléases guidées par arn |
| US20210177832A1 (en) | 2018-08-20 | 2021-06-17 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
| US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| WO2020186101A1 (fr) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Procédés de détection, compositions et méthodes de modulation des cellules de sarcome synovial |
| EP3942023A1 (fr) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions et méthodes de modulation de régulateurs métaboliques de pathogénicité de lymphocytes t |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| US20220226464A1 (en) | 2019-05-28 | 2022-07-21 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| US20220282333A1 (en) | 2019-08-13 | 2022-09-08 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| WO2021041922A1 (fr) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Systèmes de transposase mu associés à crispr |
| JP2022547570A (ja) | 2019-09-12 | 2022-11-14 | ザ・ブロード・インスティテュート・インコーポレイテッド | 操作済みのアデノ随伴ウイルスキャプシド |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
| WO2023003404A1 (fr) * | 2021-07-21 | 2023-01-26 | 한국생명공학연구원 | Nouveau récepteur antigénique chimérique et cellules immunitaires l'exprimant |
| WO2024077256A1 (fr) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Procédés et compositions pour la découverte à haut débit de protéines de liaison ciblant un peptide-cmh |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4792447A (en) * | 1981-07-23 | 1988-12-20 | Board Of Regents, The University Of Texas System | Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors |
| US5977316A (en) * | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
| ATE475428T1 (de) * | 2000-03-29 | 2010-08-15 | Univ Ohio State Res Found | Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen |
| US7514537B2 (en) * | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| LT2805728T (lt) * | 2003-12-23 | 2020-05-25 | Genentech, Inc. | Nauji anti-il 13 antikūnai ir jų naudojimai |
| EP1928912A4 (fr) * | 2005-09-07 | 2010-02-24 | Medimmune Inc | Anticorps anti-recepteur eph conjugues a des toxines |
| US7968687B2 (en) * | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
| DE102010039018B4 (de) * | 2010-08-06 | 2013-02-28 | Technische Universität Dresden | Anti-La Antikörper und ihre Anwendung zum Immunotargeting |
| JP5947311B2 (ja) * | 2010-12-09 | 2016-07-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用 |
| US9233125B2 (en) * | 2010-12-14 | 2016-01-12 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer |
-
2013
- 2013-07-12 AU AU2013289970A patent/AU2013289970A1/en not_active Abandoned
- 2013-07-12 MX MX2015000428A patent/MX2015000428A/es unknown
- 2013-07-12 WO PCT/US2013/050272 patent/WO2014011987A1/fr active Application Filing
- 2013-07-12 JP JP2015521840A patent/JP2015525765A/ja active Pending
- 2013-07-12 US US14/408,851 patent/US20150140019A1/en not_active Abandoned
- 2013-07-12 CA CA2878856A patent/CA2878856A1/fr not_active Abandoned
- 2013-07-12 BR BR112015000310A patent/BR112015000310A2/pt not_active Application Discontinuation
- 2013-07-12 CN CN201380037380.XA patent/CN104507537A/zh active Pending
- 2013-07-12 SG SG11201408398UA patent/SG11201408398UA/en unknown
- 2013-07-12 KR KR20157000921A patent/KR20150030724A/ko not_active Application Discontinuation
- 2013-07-12 EP EP13816421.5A patent/EP2872218A4/fr not_active Withdrawn
- 2013-07-12 IN IN10889DEN2014 patent/IN2014DN10889A/en unknown
- 2013-07-12 EA EA201590207A patent/EA201590207A1/ru unknown
-
2015
- 2015-01-12 IL IL236679A patent/IL236679A0/en unknown
-
2018
- 2018-12-11 US US16/216,460 patent/US20190367610A1/en not_active Abandoned
-
2022
- 2022-05-03 US US17/735,624 patent/US20230034117A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2878856A1 (fr) | 2014-01-16 |
| SG11201408398UA (en) | 2015-02-27 |
| IL236679A0 (en) | 2015-02-26 |
| US20190367610A1 (en) | 2019-12-05 |
| US20150140019A1 (en) | 2015-05-21 |
| EP2872218A1 (fr) | 2015-05-20 |
| US20230034117A1 (en) | 2023-02-02 |
| EA201590207A1 (ru) | 2015-05-29 |
| AU2013289970A1 (en) | 2015-01-22 |
| EP2872218A4 (fr) | 2016-07-06 |
| WO2014011987A1 (fr) | 2014-01-16 |
| MX2015000428A (es) | 2015-03-12 |
| BR112015000310A2 (pt) | 2017-06-27 |
| CN104507537A (zh) | 2015-04-08 |
| JP2015525765A (ja) | 2015-09-07 |
| KR20150030724A (ko) | 2015-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10889A (fr) | ||
| NZ705910A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
| IN2014DN09098A (fr) | ||
| WO2014062697A3 (fr) | Conjugués d'administration de médicament contenant des acides aminés artificiels et procédés d'utilisation | |
| NZ701573A (en) | Carriers for improved drug delivery | |
| MX366130B (es) | Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos. | |
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| NZ726488A (en) | Compositions and methods for transmucosal absorption | |
| MX358940B (es) | Compuestos terapéuticamente activos y sus métodos de uso. | |
| PH12015500084A1 (en) | Rspo3 binding agents and uses thereof | |
| PH12015500664A1 (en) | Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents | |
| MX2021015735A (es) | Composiciones de nucleasa terapeuticas y metodos. | |
| PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| WO2012038504A3 (fr) | Produits thérapeutiques contre le cancer du sein | |
| WO2013163303A3 (fr) | Aptamères du récepteur de la transferrine et administration ciblée d'aptamères | |
| EP2836501A4 (fr) | Aptamères d'arn pour la délivrance thérapeutique et diagnostique à des cellules cancéreuses pancréatiques | |
| IN2014MN01945A (fr) | ||
| WO2013071056A3 (fr) | Polythérapie médicamenteuse pour le traitement de tumeurs solides | |
| PH12015500663A1 (en) | Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents | |
| SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| IN2015MN00001A (fr) | ||
| MX2014010714A (es) | Terapia de combinacion de procaspasa para gliobastoma. | |
| IN2014DN09437A (fr) |